Cancer stem cells: controversies in multiple myeloma
โ Scribed by Sarah K. Brennan; William Matsui
- Publisher
- Springer
- Year
- 2009
- Tongue
- English
- Weight
- 247 KB
- Volume
- 87
- Category
- Article
- ISSN
- 0946-2716
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
High-dose therapy with autologous stem cell transplantation (ASCT) has been extensively used in the past 15 years in multiple myeloma. The IFM 90 trial has shown that autologous bone marrow transplantation (BMT) is superior to conventional chemotherapy in terms of response rate, event free survival,
## Abstract ## BACKGROUND Multiple myeloma (MM) is the most common indication for highโdose chemotherapy with autologous stem cell transplantation (ASCT) in the U.S. and can be associated with substantial morbidity. Thorough assessment and understanding of symptoms and risk factors for symptom dev